Insider · CIK 0001956550
Janet Loesberg
Files at AMAM (Ambrx Biopharma, Inc.). First filing -, latest -.
In brief
Janet Loesberg files SEC Form 4 as director at AMAM (Ambrx Biopharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Janet Loesberg has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -12,142 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -30,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -15,000 | - | - | 0 | Mar 7, 2024 |
Questions about Janet Loesberg
Answered from the filings on this page, as of the latest one.
Is Janet Loesberg buying or selling?
Janet Loesberg has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Janet Loesberg's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Janet Loesberg has 0.
Where does Janet Loesberg file Form 4?
Janet Loesberg has filed Form 4 at AMAM (Ambrx Biopharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.